Abstract:
Glycosmis pentaphylla, a plant species widely distributed in tropical and subtropical regions, has garnered attention in traditional medicine for its purported therapeutic properties. This study aimed to assess the antioxidant, anti-diabetic, and antipyretic activities of Glycosmis pentaphylla extracts using in vitro and in vivo experimental models. A phytochemical examination of Glycosmis pentaphylla revealed the presence of flavonoids, phenol, carbohydrates, tannin, Saponin, and alkaloids. Additionally displayed is the antioxidant activity (IC50=9.072), which is contrasted with the standard ascorbic acid (IC50=17.937). There is a notable contrast between the fasting glucose levels of the control group (5.91 mmol/L), the sample group (200 mg) (4.45 mmol/L) & the sample group (400 mg) (4.22 mmol/L). After two hours, the control group's glucose level rises to 7.65 mmol/L, while the sample (200 mg) group's level is lower at 6.78 mmol/L & sample (400 mg) level also lower 6.56, compared to the standard tolerance level. The sample group, which received extract, managed to decrease OGTT levels. The fever reduction effect was statistically significant in 250 and 500 mg/kg doses of the crude extract starting at 1 hr after administration, while the effect of the lower dose of the crude extract (250 mg/kg) was observed to be significant 3% reduction. The antipyretic effect of the crude extract at its maximum dose level (500 mg/kg) was reduced 4-5%. Further investigations are warranted to elucidate the underlying mechanisms and identify bioactive compounds responsible for these pharmacological activities, paving the way for the development of novel therapeutic agents derived from natural sources.
